SEC Form 4 · accession 0001144204-18-053712
Edesa Biotech, Inc. · EDSA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank R. Oakes
Officer — President & CEO · Director
Period of report
Oct 12, 2018
Accepted (ET)
Oct 12, 2018 · 9:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001540159
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, without par valueF2 | Oct 12, 2018 | S | 3,000 | $1.31 | D | 51,924 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were sold pursuant to a trading plan adopted by the reporting person in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- F2The Issuer completed a 1-for-7 reverse share split of its common shares effective May 4, 2018. The amount stated reflects the post-split adjustment. Fractional shares resulting from the reverse share split were rounded to the nearest whole share.